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ABSTRACT
Purpose Long-acting injectables (LAIs) are increasingly recog-
nized as an effective therapeutic approach for treating chronic
conditions. Many LAIs are formulated to create a poorly soluble
depot from which the active agent is delivered over time. This
long residing depot can cause localized chronic-active inflamma-
tion in the tissue, which has not been well defined in the literature.
The purpose of this work is to establish an experimental baseline
for describing these responses.
Methods Non-human primates and rodents were used to ex-
amine the response to LAI formulations of two clinically relevant
atypical antipsychotics, aripiprazole monohydrate and olanzapine
pamoate monohydrate.
Results A foreign body response develops with elevations of key
cytokines such as IL-1α, IL-1β, TNFα, and IL6 at the site of
injection. However, the tissue response for the two atypical
antipsychotics compounds diverge as evidenced by quantitative
differences observed in cytokine levels at various time points after
dosing.
Conclusions Our studies show that, while the drugs are in the
same therapeutic class, the response to each of these compounds
can be distinguished qualitatively and quantitatively, supporting the
idea that the injection site reaction involves a multiplicity of factors
including the properties of the compound and cellular dynamics at
the site of injection.
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ABBREVIATIONS




FBR Foreign body response
IS Injection site
ISR Injection site reaction
LAI Long-acting injectable
OLZ Olanzapine pamoate monohydrate
PBMC Peripheral blood mononuclear cells
INTRODUCTION
The key to optimal efficacy of many drugs is sustained sys-
temic exposure to therapeutic concentrations of the active
compound. Long-acting injectable (LAI) drug products are
designed to provide this prolonged exposure. LAIs are usually
delivered either subcutaneously or intramuscularly, enabling
slow drug release over an extended period of time (1). There
are a wide variety of approaches used for LAI delivery includ-
ing microsphere technology, liposomal encapsulation, nano-
and microcrystalline dispersions, lipophilic solutions, oil-based
emulsions, and implants. LAIs are available for a wide range
of medical indications, and interest in this area continues to
grow because of LAIs impact on adherence and improved
patient outcome (1). The area of atypical antipsychotics
(ATAPs), which are used in the treatment of schizophrenia,
bipolar disorder and depression, has seen major advances in
recent years including LAIs of important drugs like risperi-
done, palperidone, olanzapine and aripiprazole (2–5).
While the LAI approach can provide sustained release over
weeks or months, the deposition of foreign materials in the
tissue bed can result in a variety of tissue responses (6, 7),
which often are characterized clinically as an injection site
reaction (ISR) or injection site granuloma. ISRs encompass a
broad range of reactions from minor events such as pain,
induration and redness to more significant tissue responses
including nodule or cyst formation and sterile abscesses (2).
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Granulomas are strictly defined as nodular inflammatory
lesions, usually small or granular, firm, persistent, and con-
taining compactly grouped mononuclear phagocytes (8).
Pathologically, granulomas are compact, organized collection
of mature mononuclear phagocytes, not necessarily accompa-
nied by accessory features such as necrosis(9). However, the
term granuloma is often used to describe any nodule forma-
tion, and is frequently used in descriptions of ISR’s.
There are several case reports in the literature
documenting sterile abscess formation with long-acting
gonadotrophin-releasing hormone agonist leuprolide,
resulting in resistance to treatment in some cases (10–12).
Subcutaneous injection of enfuvirtide, an antiviral treatment
for HIV, results in granuloma formation at the site of injection
in a large proportion of patients, as determined by patholog-
ical analysis (13, 14). Adalimumab, used in the treatment of
rheumatoid arthritis and other autoimmune disorders, is re-
ported to cause lesions and interstitial granulomatous drug
reactions (15). Despite these case reports, detailed reports
describing the ISR and local tissue response to LAIs are
scarce, with minimal characterization of the local cellular
and cytokine changes to these responses.
Atypical antipsychotics, also known as second-generation
antipsychotics, have an array of pharmacologic actions includ-
ing blockade of dopamine receptors. They also tend to have
high efficacy in patients without causing a number of the side
effects seen with first-generation antipsychotics, such as extra-
pyramidal motor control disabilities (16). LAI formulations of
ATAPs have been recently developed for the treatment of
these disorders. These include risperidone (Risperdal®
Consta®), a polymer microsphere formulation first approved
in 2002, a nano-crystalline formulation of paliperidone pal-
mitate (Invega® Sustenna®), approved in 2009, olanzapine
pamoate monohydrate (Zyprexa Relprevv®) also approved in
2009, and most recently, aripiprazole monohydrate (Abilify®
Maintena™) was approved in 2013. These products provide
continual exposure to therapeutic concentrations in systemic
circulation over weeks and months with reduced peaks
and troughs in plasma drug concentration. Additionally,
LAIs for these medications are administered by health
care professionals to ensure compliance and improve
therapy for schizophrenia, bipolar disorder and depression
(1, 17–20).
As with the other LAIs, these formulations of antipsychotics
may also result in clinically defined ISRs. Depot oil-based
injections of the first-generation antipsychotic haloperidol
(Haldol® Decanoate®) cause injection site reactions, leading
some patients to discontinue treatment (21, 22). LAI formu-
lations of atypical antipsychotics risperidone and paliperidone
palmitate have reduced incidences of ISRs compared to hal-
operidol decanoate, possibly due the fact that these are
aqueous-based injections. Nevertheless, redness, pain, swell-
ing, and nodule formation at the site of injection have been
reported with both these compounds (3, 23–26). The LAI
formulation of olanzapine pamoate monohydrate (Zyprexa
Relprevv®) has an incidence of injection site reactions of
8.4%, similar to what was reported with haloperidol (4, 27,
28). Aripiprazole monohydrate (Abilify® Maintena™), re-
cently approved by the U.S. Food and Drug Administration
(FDA)-as an extended release formulation, has a reported
injection site-related adverse events of 6.3%, with investigator
evaluation noting injections site pain, redness, swelling, and
induration in 4–26% of subjects in open label stabilization
phase studies (38), (29). The work described in this paper
was undertaken to characterize the immunological and
cellular changes associated with the administration of
aripiprazole monohydrate and olanzapine pamoate
monohydrate in both non human primates and rodents.
The findings are characterized by the histopathology of
the FBR resulting from the depot injections in both models
and bymonitoring the release of various cytokines after dosing
in rodents.
MATERIALS AND METHODS
Preparation and Formulation of Compounds
Aripiprazole monohydrate was prepared by adding
aripiprazole anhydrous free base (Matrix Labs, India) to a
0.2% polysorbate 20 solution (JT Baker, Philipsburg NJ) in
phosphate buffered saline (Sigma, St Louis MO). The
resulting mixture was left stirring for several days to ensure
complete conversion to aripiprazole monohydrate. The solids
were then collected using a Hirsch funnel, washed with water
and dried in vacuo to give aripiprazole monohydrate as a
colorless solid. Particle size distribution was measured using
a Horiba LA910 to give average volume metrics of dv10=
1 μm, dv50=5 μm, dv90=13 μm. Full characterization, in-
cluding powder X-ray diffraction, fourier transform infrared
spectroscopy, differential scanning calorimetry, and thermo-
gravimetric analysis was also conducted.
Olanzapine pamoate monohydrate was prepared by
adding olanzapine-free base (Neuland Lab Limited, India) to
dimethyl sulfoxide (DMSO) (Sigma, St Louis MO) in a flask.
The resulting mixture was shaken and sonicated to ensure
dissolution of the solids. The solution was then added to a
separate flask containing pamoic acid (Sigma, St Louis MO).
The flask containing olanzapine was then washed with twice
with DMSO and all contents were combined. The organic
solution containing olanzapine and pamoic acid was then
added to another flask containing water. The resulting mix-
ture was heated to 40°C and stirred for 20 min. The solution
was then cooled to 25°C and the resulting precipitate was
collected using a Hirsch funnel and washed with water. The
powder was dried in vacuo at 50°C overnight to yield
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olanzapine pamoate monohydrate as a yellow solid. Particle
size distribution was measured to give average volume metrics
of dv10=2.8 μm, dv50=7.4 μm, dv90=16.0 μm, and full
characterization, including powder X-ray diffraction, fourier
transform infrared spectroscopy, differential scanning calo-
rimetry, and thermogravimetric analysis was also conducted.
The formulations of aripiprazole monohydrate and
olanzapine pamoate monohydrate used in animal studies
were prepared to provide 100 and 300 mg/ml suspension
by adding either 3 g or 9 g to a 50 ml glass vial. To the solids
was added 30 ml of injection vehicle (2–3% sodium CMC,
0.2% polysorbate 20 in phosphate buffered saline (PBS)
pH 7). The resulting mixture was sonicated for 10 min and
left standing. The contents of the vial were then shaken until a
uniform; clump-free suspension was obtained prior to dosing.
Animal Studies
Rodents
Rodents were housed and maintained following the recom-
mendations of the Institute of Laboratory Animal Resources
Guide for the Care and Use of Laboratory Animals, 7th Ed.
(30) . All experiments were approved by Alkermes’ IACUC.
Sprague Dawley rats were obtained from Charles River
Laboratory between 6 to 8 weeks of age and weighed between
225 and 250 g. Animals were housed two per cage with
environmental enrichment, at 64–76 F and using a 12-h
light/12-h dark cycle. Food and water were provided ad libitum.
Rats were allowed to acclimate to housing for at least 1 week
after arrival in the facility before being assigned to a study.
Cynomolgus Monkey
Single dose intramuscular or subcutaneous toxicology study in
cynomolgus monkeys (Macaca facicularis) was conducted by an
external research organization in accordance with the US FDA
Good Laboratory Practice Regulations (Part 58 of 21 CFR),
following the recommendations of the Institute of Laboratory
Animal Resources Guide for the Care and Use of Laboratory
Animals, National Academy Press 1996, and in accordance
with all appropriate parts of the Animal Welfare Act regula-
tions. Animals were pair housed during the study. Primate diet
was provided twice daily and suplemented three times a day
with fruits and vegetables. Water was provided ad libitum.
Animal Studies
Cynomolgus Monkey Study
For this study, 18 male cynomolgus monkeys between the ages
of 2.75 and 4 years with amean weight of 3.2 kg were used. The
animals were dosed once either intramuscularly in the gluteal or
gastrocnemius muscle group or subcutaneously on the dorsal
surface with aripiprazole monohydrate in 3% carboxymethyl-
cellulose, 0.1% polysorbate 20 and 0.9% sodium chloride in
sterile water as vehicle (Table I). An additional 4 animals were
injected intramuscularly with vehicle only as controls. A volume
of 0.5 ml/kg was used for all materials. The animals were then
observed for 30 day, after which 16 of the animals were hu-
manely euthanized and necropsied. Animals were sedated with
ketamine/xylazine and then euthanized by exsanguination un-
der sodium pentobarbital anesthesia. The remaining 6 animals
were further observed for a 20 day period to determine if there
was recovery from any effects seen. After this recovery period,
the animals were euthanized as described above. A full post-
mortem examination was conducted on the animals including
macroscopic and microscopic pathology.
Rodent Studies
For experiments conducted to determine threshold dose for
localized tissue responses, five groups (n=6 per group) of
Sprague Dawley rats were sedated with isoflurane and then
injected in the intrascapular region with aripiprazole
monohydrate or olanzapine pamoate monohydrate at a dose
of 3, 10, 30, 100 or 300 mg/site for each drug using a 21-
gauge, 1-in. needle attached to a 1-cc syringe. The dose
volume was 1.0 ml for all groups. The animals were continu-
ously monitored until they recovered fully from the anesthesia.
Ten days following injection, animals were euthanized by
carbon dioxide asphyxiation, and the injection site was excised
and weighed. The injection sites were defined as the drug
depot and surrounding tissue.
For time course experiments, rats were dosed via syringe
subcutaneously in the intrascapular region using a 21-gauge
needle as described above. On days 1, 3, 7, 10, 14, and 21,
three animals per group were euthanized by carbon dioxide
asphyxiation. Whole blood was obtained from the animals
post mortem by cardiac puncture and up to 10 ml of blood
collected. The injection sites were excised and placed on ice
for further processing.
Peripheral Blood Mononuclear Cells and Fluid Isolation
Whole blood from rats was placed in an EDTA Vacutainer®
tube (BD, Franklin Lakes NJ, catalog # 366643), mixed
Table I Experimental Design for Cynomolgus Monkeys
Number of animals Aripiprazole dose (mg/kg) Route 30 day 50 day
4 0 IM 4 0
6 15 IM 4 2
6 120 IM 4 2
6 120 SC 4 2
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thoroughly, and rested at room temperature for 15 min.
Blood was then mixed with 1.25 ml of Optiprep™ media
(Axis, Oslo Norway catalog #1114542) in a 50 ml conical.
One milliliter of Tris-buffered saline (TBS) was layered on top
of the blood/Optiprep™ mixture, and spun at 1,200 g for
30 min at room temperature. After centrifugation, the buffy
coat was isolated and transferred to a 15 ml conical. The cells
were then washed in 10 ml of PBS (Lonza, Walkersville MD),
centrifuged again to remove any residual fluid, and were then
subjected to red blood cell lysis (RBC lysis buffer, R7757
Sigma-Aldrich, Saint Louis MO). The cells were then washed
twice and resuspended at a concentration of 107 cells per
milliliter.
Serum was isolated by adding 1 ml of whole blood to
Microtainer® serum separator tubes (BD, Franklins Lakes
NJ 365956). The blood was incubated on ice for one hour,
and then centrifuged at 14,000×g for 3 min. The serum was
removed from the tube and immediately frozen at −80°C for
later cytokine analysis.
Processing of Injection Sites and Surrounding Tissue
Response
Injection sites were isolated from euthanized animals and
immediately placed on ice. Fluid contained within the struc-
ture was aspirated with a 21-gauge needle using a 1-cc tuber-
culin syringe. Immediately following collection, fluid was
placed on ice and then frozen at −80°C for cytokine analysis.
The injection sites were dissected on ice and then centrifuged
at 3,000×g to obtain additional fluid, which was pooled with
the original aspirate; typically this yielded no more than 10%
of the total recovered volume. The remaining tissue was
frozen and stored at −80°C.
Cytokine Analysis
Cytokines levels were measured in both sera and fluid obtain-
ed from the injections site by multiplex analysis using a Bio-
Plex Pro™ rat cytokine group 1 custom 13 plex assay which
contained the following targets: IL-1α, IL-1β, IL-2, IL-6, IL-
10, IL-12p70, IFNγ, GRO/KC, MIP-1α, MIP-3α,
RANTES, TNF, and VEGF (Bio-Rad, Hercules CA,
Catalog #L8000LED47). The assay protocol provided with
the kit was followed for these analyses. Assay plates were
processed on a Luminex® 200. Data were analyzed using
the xPONANT 3.1 software.
Determination of Cell Populations
PBMCs from whole blood were isolated as described above.
Cells were then resuspended in 100 μL FACS buffer com-
prised of PBS (Lonza, Walkersvile MD) containing 1% fetal
calf serum (FCS) (GIBCO®, Carlsbad, CA catalog #16000-
077) and 1 μg of anti-rat CD23 (BD, San Jose CA, catalog
#550270) FC block at a concentration of 106 cells/ml. Cells
were incubated at 4°C for 15 min and then stained for surface
markers to determine cell populations in whole blood. All
antibodies were obtained from BD Biosciences (San
Jose, CA). Markers examined were RP1 (550002), CD4
(561578), CD8a (558824), HIS48 (554907), HIS 36
(554901), CD11b/c (554861), and CD161 (555009). After
staining, the cells were analyzed on an Attune® flow
cytometer (Applied Biosystems® Carlsbad, CA).
Statistical Analysis
Data are expressed as either means±standard deviation or as
individual points with bars indicating the means. Statistical
analyses were performed using GraphPad Prism® 5 and SAS
9.2. Two-way analysis of variance (ANOVA) were conducted
on cytokine and cell data, with statistical significance
established at p<0.05.
RESULTS
Intramuscular or Subcutaneous Injections
of Aripiprazole Monohydrate Results in Chronic-Active
Inflammation in non-Human Primates
It has been reported that depot injections of atypical antipsy-
chotics may cause pain or swelling to occur in patients during
clinical trials of many different compounds. To investigate this
occurrence, cynomolgus monkeys were injected with
aripiprazole monohydrate (APZ) once either subcutaneously
with 120 mg/kg, or intramuscularly with 15 mg/kg or
120 mg/kg respectively, and then observed for 30 to 50 days
(Table I). As controls, all animals were injected with the
vehicle in the contra-lateral leg. Also, a separate control group
were injected with vehicle alone and observed for the same
period of time. After 30 days, the control animals and 4
animals per test group were humanely euthanized and
necropsied, while 2 animals per test group recovered for 20
days before being euthanized (Table I). The injection sites
were also subjected to analysis by a pathologist to assess
inflammation state. Six days after injection, discrete masses
were detected at the injection site in all the animals that had
received subcutaneous injections, and were present through-
out the test and recovery period. These masses ranged in area
from 1.5 cm2 to 14 cm2. Upon necropsy at day 30 and 50,
visible masses were present at the injection site bymacroscopic
analysis, along with chronic-active inflammation at the injec-
tion site as determined by microscopic analysis (Table II).
Chronic-active inflammation is defined as infiltrates of foamy
macrophages lined by lymphocytic aggregates and central
areas of necrosis as determined by a pathologist. In the
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animals injected subcutaneously, the injection sites also had
clear central areas. Pathological analysis determined that this
chronic-active inflammation in the subcutaneous group to be
marked to severe severity at both time points, indicating that
there was an ongoing local immune response to the LAI
(Table II).
There was also indication of long duration chronic-active
inflammation in the animal groups that received intramuscu-
lar injection. One animal who received a 120 mg/kg injection
had a distinct mass present at the injection site accompanied
by hemorrhage, erythema, and ulceration not believed to be
due to microbial presence at day 30. This animal was
necropsied at day 30, and was seen to have marked chronic
inflammation at the site of injection (Table II). A second
animal in this dose group had indications of moderate chronic
inflammation at the injection site at 30 days, while one in the
15 mg/kg group had slight inflammation at the site (Table II).
The data from this study reveled that there was a significant
localized reaction occurring at the site of injection with
aripiprazole monohydrate, and that it was more pronounced
in the subcutaneous space.
Local Tissue Response Following Subcutaneous
Administration of Aripiprazole Monohydrate
in Rodents
The studies in non-human primates illustrated that there was
a significant local tissue response to aripiprazole monohydrate
depots, especially in the subcutaneous space. Therefore, fur-
ther studies were conducted in the subcutaneous space in
rodents. In order to determine the dose response curve of
local tissue reaction to subcutaneous aripiprazole
monohydrate (APZ), increasing doses were administered to
rats and the injection sites evaluated 10 days later. The tissue
response was characterized by a non-linear dose response
curve (Fig. 1a). At doses up to 30 mg, the mass of the injection
site, which is defined as the depot and any resultant encapsu-
lating structure, and the surrounding inflamed tissue, was
relatively low with a clear inflection point in the response
curve occurring at the 100 mg dose. Consequently, additional
studies were conducted using 100 and 300 mg of APZ since
these doses initiated robust responses.
The response resulting from SC injection of 100 and 300mg
was further characterized over a 21-day period. The weights of
the injection sites are shown in Fig. 1b. One day following the
injection of APZ, a loose, gelatinous-like material was present
surrounding the boundaries of the injection site. By day 3, a
well defined fibrous capsule surrounded the site. The weight is
significantly affected by the dose (p<0.0001) after 10 days
(Fig. 1a). The dose-by-time interaction (p=0.011) is also signif-
icant from days 3 to 21, as illustrated in the time courses in
Fig. 1b. At the 100 mg dose of APZ, the weights were relatively
constant between days 3 and 10 and then began to decrease. In
contrast, at the 300 mg dose the weight of the IS increased
between days 3 and 10 and then remained constant; the sites
did not appear to diminish in size through day 21 (Fig. 1b). A
control group that only received injections of vehicle showed no
indication of inflammation or encapsulation at any time point,
nor was there any fluid present at the site.
While the injection site was less well defined on day 1
(Fig. 2a), it was readily recognizable. By day 7, a distinct
fibrous capsule is present surrounding a fluid-filled cavity
(Fig. 2b). This encapsulated structure’s wall thickens in this
time frame, and extrudate begins to accumulate inside the
structure along with cellular debris. This extrudate generally
appears yellow and translucent, and contains cellular debris
that is either particulate or creamy in consistency. The in-
crease in the mass of the IS between days 7 and 14 is due
primarily to the increase in fluid contained inside the struc-
ture. There was also significant infiltration of mononuclear
cells around the site, indicating a productive immune response
(Fig. 2). By day 14, the structures associated with 100 mg of
APZ had begun to decrease in size, indicating a process of
resolution, with portions of the structure compacting and
forming into a nodule and a reduction in the amount of fluid
and debris contained within the structure, however with
300 mg doses, they are still increasing in size (Fig. 2c). By
day 21, the capsule resulting from SC administration of a
Table II Incidence of Chronic-
Active Inflammation in Cynomolgus
Monkeys Following Injection
of Aripiprazole Monohydrate
30 day observations 50 day observations
Dose (mg/kg) 0 15 120 120 15 120 120
Number of animals examined 4 4 4 4 2 2 2
Route of injection IM IM IM SC IM IM SC
Minimal 0 0 0 0 0 0 0
Slight 0 1 0 0 1 0 0
Moderate 0 0 1 0 0 0 0
Marked 0 0 1 1 0 0 0
severe 0 0 0 3 0 0 2
Total incidence 0 1 2 4 1 0 2
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100 mg dose of APZ contained negligible fluid, resulting in a
structure containing a firm nodule. When a 300 mg dose is
administered, the tissue response surrounding the injection
site continues to increase in size up to at least day 21
(Fig. 2d). This increase in size is reflective of the fact that the
capsule continues to accumulate fluid inside the structure. The
structure wall thins out as the IS increased in size, but never-
theless the wall remains intact and fibrous (Fig. 2d). At day 21,
red coloration to the extrudate was also seen inside the struc-
ture (Fig. 2d).
Key Inflammatory Cytokines are Involved in the Foreign
Body Response to Aripiprazole
A significant tissue response following SC injection of APZ has
been described. The response displays the key characteristics
of a foreign body response (FBR). In order to evaluate the
immunological characteristics of this FBR, key inflammatory
proteins which may contribute to the formation and mainte-
nance of the tissue response were examined. IL-1α (Fig. 3a)
and IL-1β (Fig. 3b), both potent pro-inflammatory cytokines
that are key regulators of the early immune response to foreign
particles, are present in elevated concentrations by day
1 and then decrease until day 7, after which time they
can no longer be detected. IL-6, an important acute-
response cytokine secreted by macrophages after injury,
and MIP3α, an early chemo-attractant, are detected in
the tissue on day 1 only. Neither IL-6 nor MIP3α can
be found in significant concentrations on subsequent days
(Fig. 3c–d).
As seen in the time courses of weights of the IS illustrated in
Fig. 1b, the response at the depot site continues until at least
day 21. During this time, as the immune system continues to
respond to the IS, there are changes in the cytokines being
expressed at the site, indicating a temporal shift in the type of
response being mounted. On day 7, there is elevation of
TNFα, which signals through NF-κB and MAPK pathways
and has pro- and anti-inflammatory roles (Fig. 4a). RANTES,
a chemotactic cytokine important in recruiting lymphocytes
and other immune cells to the site of inflammation is also
observed (Fig. 4b). Both TNFα and RANTES are integral to
the maintenance of the immune response. VEGF, a signal
protein that stimulates angiogenesis and vascularization, is
additionally elevated (Fig. 4c). VEGF aids in vascularization
of the fibrous capsule, and significant levels of this cytokine are
observed as early as day 1 and are generally peaking by day 3,
thoughVEGF levels remain high out to 21 days. The presence
of these cytokines indicates that there is a significant and
sustained FBR to aripiprazole deposited in the subcutaneous
space. Indeed, the cytokine profiles helps explain the macro-
scopic character of the injection sites as they evolve in response
to the APZ depot.
Foreign Body Response Observed with Olanzapine
PamoateMonohydrate Following SubcutaneousDosing
In order to determine if the tissue response seen with subcu-
taneous injections of APZ were unique to the compound,
analogous studies were conducted with another atypical anti-
psychotic, olanzapine pamoate monohydrate (OLZ). OLZ
was injected subcutaneously into rats as a function of increas-
ing dose. Similar to the situation with APZ SC doses, the
threshold dose of OLZ for inducing a significant tissue re-
sponse was at 100 mg, at which point the weight of the
encapsulated structure and surrounding tissue increases sig-
nificantly compared to what is seen at lower doses (i.e. up to
30 mg; Fig. 5a). Upon examination of responses to the higher
doses over time, the encapsulated structure weight increased
up to day 7, and then decreased slowly with time at both
100 mg and 300 mg doses (Fig. 5b). Experiments conducted
with vehicle alone or with water soluble sodium pamoate at
equivalent concentrations resulted in no FBR after 24 and
72 h (data not shown).
The early response profile for OLZ is similar to that seen
with APZ, with tissue and fluid surrounding the encapsulated
structure on day 1 (Fig. 6a). However, while fibrous capsule is
Fig. 1 Dose and time response to aripiprazole monohydrate injected subcutaneously in rats. (a) Weight of injection site (IS) 10 days following subcutaneous injection
of APZ in 3% CMC, 0.1% polysorbate 20, 0.9% NaCl in increasing doses. Average weight is shown in graph with standard deviation (SD), n=6 per dose. (b)
Weight of the IS over time for two doses of APZ in 2% CMC and 0.2% polysorbate 20. Two-way analysis of variance shows a significant dose (p=<0.0001) and
dose×time (p=0.0011) effect.
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formed by day 3 (data not shown), negligible fluid or cellular
debris is found within the structure associated with OLZ
injection. The structures increase in size up to day 7
(Fig. 6b), at which point fluid and cellular debris are seen
inside the structure. The wall of the structure, while fibrous
and well vascularized, is thin and easily ruptured. The content
includes material having the bright yellow color of OLZ
(distinct from APZ, which is white in appearance). The
structure begins to decrease in weight and fluid content after
day 7, and formed into nodules by day 14 (Fig. 6c). This
nodule is still present on day 21, but continues to decrease in
size and throughout contains limited fluid (Fig. 6d). These
observations demonstrate that while a similar tissue response
is observed with OLZ (Fig. 5) and APZ (Fig. 1), there are key
differences in terms of size, histological features, and rate of
resolution.
Fig. 2 Histological observations of
aripiprazole monohydrate injection
sites. Micrographs of the IS excised
from euthanized rats at (a) day 1, (b)
day 7, (c) day 14, and (d) day 21
following SC administration of
300 mg of aripiprazole
monohydrate. The structures and
surrounding tissue are shown at
0.5× magnification following H&E
staining. Scale bars are 5 mm. Slides
are representative of four animals
per time point.
Fig. 3 Early cytokines involved in
the ISR to aripiprazole
monohydrate. (a) IL-1α, and
(b) IL-1β cytokine levels measured
in fluid extracted from the
encapsulated structure at either
100 mg/ml or 300 mg/ml doses of
APZ. Fluid for the analysis was
separated from tissue by
centrifugation. Cytokine levels from
each animal are plotted with bars
indicating mean (n=3 per time
point and dose). (c) IL6 and (d)
MIP3α cytokine levels were
examined in fluid extracted from the
encapsulated structure at either
100 mg/ml or 300 mg/ml doses of
APZ. Fluid for the analysis was
separated from tissue by
centrifugation. Cytokine levels from
each animal are plotted with bars
indicating mean (n=3 per time
point and dose).
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Key Inflammatory Cytokines Present in the FBR
to Olanzapine Pamoate Monohydrate
and in Surrounding Tissues
The differences seen in terms of the gross morphology of the
response to APZ and OLZ may be due to differences in FBR
cytokine expression. Therefore, multiplex analysis was per-
formed on samples of the tissue surrounding the encapsulated
structure resulting from injection of OLZ. While IL-1α levels
are low (Fig. 7a) in the days following subcutaneous injection,
the tissue around the encapsulated structure has high levels of
IL-1β (Fig. 7b), IL-6 (Fig. 7c) and MIP3α (Fig. 7d). These
elevated levels of IL-1β, IL-6 and MIP3α however are reduced
overall from what is observed with APZ in the encapsulated
structure. These early differences indicate that OLZ
induces a FBR different from that induced by APZ.
The differences presumably influence the morphology
and duration of the tissue response to the foreign material.
The cytokines seen later in the response to OLZ are similar
in type, but reduced in quantity compared to APZ response.
Both TNFα (Fig. 8a) and RANTES (Fig. 8b) are elevated
between days 7 and 10. TNFα levels continue to rise through
day 21, although the overall response appears limited.
RANTES levels peak at day 10, and decrease throughout
Fig. 4 Later cytokines involved in
the ISR to aripiprazole
monohydrate. (a) TNFα is elevated
at day 1, then again between days 7
and 14 after SC injection of APZ.
Fluid for the analysis was separated
from tissue. (b) RANTES levels
begin to be elevated at day 7, peak
between days 10–14, and are
reduced by day 21. (c) VEGF is
elevated in the tissue surrounding
the encapsulated structure later in
the response time frame. Cytokine
levels from each animal are plotted
with bars indicating mean
(n=3 per time point and dose).
Fig. 5 Dose and time response to olanzapine pamoate monohydrate injected subcutaneously in rats. (a) Weight of injection site, which includes the encapsulated
structure and surrounding tissue, after subcutaneous injections with OLZ in 3% CMC, 0.1% polysorbate 20, 0.9%NaCl at a range of doses at day 10. Average
weight of tissue response is shown in graph with standard deviation, n=6 per group. (b) Structure weight in response to 100 mg or 300 mg OLZ in 1 ml 2%
CMC, 0.2% polysorbate 20 over time. Two way analysis of variance shows a significant dose (p=<0.0001), time (p=<0.0001), and interaction (p=0.03)
effect. The average FBR weight is plotted with error bars indicating standard deviation (n=3 per time point and dose).
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the remainder of the observation period. VEGF was also
present at the structure (Fig. 8c), although it is induced later
in the response and exhibits peak levels at day 7. VEGF levels
then steadily decrease over time in parallel with the decreasing
size of the IS.
The pattern emerging from this data is that while the FBR
formed as a result of subcutaneous injection with two poorly
soluble ATAPs are similar in many respects, there are also key
differences indicating that the tissue responds in a distinct
manner to each compound. Given that material amounts
were matched between the experiments with the two insoluble
drugs, particle size distributions were in a similar ranges, and
both are highly water-insoluble and thus resident and detect-
able in the sites for the duration of the experiment, it is likely
that the details of the pharmacological profile of the deposited
compound play a role in the response.
Fig. 6 Histological observations of
olanzapine pamoate monohydrate
injection sites. Micrographs of the
encapsulated structure and
surrounding tissue, comprising the
injection site, The IS excised from
rats at (a) day 1, (b) day 7, (c) day
14, and (d) day 21 following SC
administration of 300 mg of OLZ.
The images are shown at
0.5× magnification following H&E
staining. Slides are representative
of four animals per time point.
Fig. 7 Cytokines involved in the
ISR to olanzapine pamoate
monohydrate. (a) IL-1α, (b) IL-1β,
(c) IL-6 and (d) MIP3α cytokines
present in encapsulated structure
and surrounding tissue after
subcutaneous injections of 300 mg
olanzapine pamoate monohydrate.
The injection site from day 3
contained no discernible fluid;
therefore cytokine levels at the site
could not be determined. Cytokine
levels from each animal are
plotted with bars indicating mean
(n=3 per time point and dose).
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FBR is a Localized Tissue Response
Following Subcutaneous Dosing of ATAPs
The proteins induced at the site of injection are potent immu-
nomodulators. If expressed systemically or released beyond
the site of injection, the cytokines would have significant effects
on the body. To evaluate whether the response was causing an
alteration in circulating immune cells, which would indicate a
systemic response to the compound, peripheral blood mono-
nuclear cells (PBMCs) were isolated from the whole blood of
rats that were injected with 300 mg APZ or OLZ and com-
pared with control samples from naïve (untreated) animals.
These cells were then stained with antibodies specific for
several important immune cell markers and then analyzed
by flow cytometry. Antibodies for CD4 (Fig. 9a), which is
representative of the T-helper cell population, CD45
(Fig. 9b) as a marker for the B cell population, and CD11B/
C (Fig. 9c) for macrophages/monocytes were used to look at
general cell populations in both treated and untreated ani-
mals. Relative percentage of total cell populations was deter-
mined and compared to those of naïve animals.
While there are day to day variations in cell populations, no
significant changes between treated and naïve animals can be
detected by analysis of variance (ANOVA) (Fig. 7). Other cell
types were also examined, including dendritic cells, neutro-
phils, CD8+ T cells and NK cells. No observable differences
could be discerned between treated and naïve animals for
these cell types (data not shown). Purified PBMCs from treat-
ed or naïve animals were examined in vitro for responsiveness
to lipopolysaccharide in order to determine if there was any
functional differences in these cells. No significant differences
in IL-6 or TNFα secretion by these cells were observed, and
there were no measurable differences in circulating serum
cytokine levels in the animals as well (data not shown). These
findings suggest that the FBR observed following subcutane-
ous dosing of an LAI ATAP does not elicit an immune
activation beyond the IS. Based on this evidence, the immune
response generated by poorly soluble ATAP injections is
localized and does not impact the overall immune status of
the animal.
DISCUSSION
The studies described here establish a baseline approach for
describing the foreign body response to LAIs which has not
previously been demonstrated. Aripiprazole monohydrate
(APZ) and olanzapine pamoate monohydrate (OLZ) were
selected as model LAIs for the study of injection site and
foreign body reactions in non-human primates and rats. The
choice of drugs was based on therapeutic relevance, physico-
chemical properties (these water-insoluble compounds both
exhibit intrinsic extended release upon subcutaneous dosing),
and the observed local tissue responses they generate (31).
While in clinical practice these materials are injected intra-
muscularly, subcutaneous dosing presented significant advan-
tages for the present study. Subcutaneous administration is
ideal as a model on account of the relevance of the route for
LAIs of various drugs, the immunological sensitivity of the SC
space, accessibility and palpability of the injection sites, and
Fig. 8 Later cytokines involved in
the ISR to olanzapine pamoate
monohydrate. Significant levels of
(a) TNF and (b) RANTES are found
at encapsulated structures and in
surrounding tissue after 300 mg
injection with 300 mg of the
olanzapine pamoate salt. (c) VEGF is
also elevated in the tissue
surrounding the structure by day 7,
but then declines over time.
Cytokine levels from each animal
are plotted with bars indicating
mean (n=3 per time point
and dose).
2074 Paquette et al.
because it allows for the administration of clinically relevant
doses in total volume, not on a mg/kg basis. As illustrated by
the non human primate data, the reaction that is seen in the
subcutaneous space also mimics what may be seen in the
intramuscular space in larger animals. Cynomolgus monkeys
are frequently used for toxicology studies as their responses
and metabolism to compounds closely resembles human re-
sponses. The data from this study demonstrate that there is a
significant local tissue response to aripiprazole monohydrate
at clinically relevant doses. Gross and microscopic pathology
shows that there was chronic active inflammation throughout
the duration of the study, indicating that the compound is
highly irritating at the site, and continues to be irritat-
ing as long as it is present in the tissue. While this
model validates clinical data available for many LAI
compounds currently in use, it is not feasible to use
for more detailed studies. Therefore, rats were used to
further describe the chronic-active inflammation process in
SC injection site.
Initial rodent experiments elucidated a dose relationship
for the FBR, as measured by weight of injection site and
surrounding tissue with increasing dose. Additionally, there
appears to be a threshold dose, ≥100 mg, above which the
tissue response, including the size of the encapsulated struc-
ture, increase disproportionately with increasing dose. This
response is characteristic of a foreign body response, which is a
distinct sterile immunological response to foreign materials or
particles implanted in the body (6, 32). After the initiation of
the FBR by the implantation of the material, soluble media-
tors such as chemokines and cytokines produced by infiltrating
inflammatory cells and the surrounding tissue regulate the
progression of the reaction (32).
Significant tissue responses are observed following SC ad-
ministration of APZ and OLZ, which, based on this charac-
terization study, represent a type of FBR. There are two
specific phases to this FBR distinguished by an early, acute
inflammation phase and a secondary, chronic inflammation
phase. The acute phase is most likely triggered by the tissue
damage resulting from the mechanical perturbation of the
subcutaneous space and the presence of the drug particles in
the depot. The cytokines present early in the response (IL6,
IL-1α, IL-1β, MIP3α) indicate a potent immune response
initially, which is characteristic of the acute-phase response
triggered by tissue damage resulting primarily from the pres-
ence of foreign material. These cytokines may also help direct
the later response to the depot and contribute to the formation
of the fibrous capsule. The secondary phase of the response is
characterized by local appearance of cytokines, chemokines,
and proteins that work to control the response despite the
continued presence of the foreign material. This chronic in-
flammation contributes both to the maintenance of the tissue
response and the wound healing characteristics that ensue.
The overall response demonstrated is similar to foreign body
responses elicited by implanted materials such as naltrexone
Fig. 9 Systemic immune cell
populations are not altered by
aripiprazole monohydrate or
olanzapine pamoate monohydrate.
PBMCs were freshly isolated from
animals on the noted time point,
purified by density centrifugation,
and stained with marker specific
fluorescent antibodies and analyzed
by flow cytometry. Cells were
stained with (a) anti-CD4, (b) anti-
CD45RA and (c) anti- CD11b/c.
Data from each animal per group is
plotted. ANOVA analysis was
performed to determine
significance.
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microspheres (33), collagen disks (34), and other implanted
biomaterials (35).
The foreign body response (FBR) is part of the host re-
sponse to tissue injury (1, 6). In this case, the FBR is being
induced due to the subcutaneous injection of the ATAPs and
the tissue injury resulting from this injection. The acute in-
flammatory response is characterized by fluid, proteins, and
blood cells leaving the vascular system and infiltrating the site
of injury. A fibrin matrix also forms at the site shortly after
mechanical injury, influencing the second phase of the FBR,
which includes the continued presence of inflammatory pro-
teins, mononuclear cells and granulation tissue at the site, and
can develop into a fibrous capsule (6).
TNFα, IL-1, and IL-6, key cytokines induced after injury,
are elevated following administration of the ATAPs investi-
gated. Mononuclear cells, characteristic of a chronic inflam-
mation response, remain at the site of injection up to day 21,
despite the formation of fibrous capsules, which are
established during the wound healing process. This is the
result of the persistent inflammatory presence of the ATAP
at the site of injection. As long as the foreign material is
present, the FBRwill continue. However, once the compound
has left the depot, the wound healing response can achieve
resolution. For example, the FBR to the 300 mg aripiprazole
suspension results in continued increase in mass at the injec-
tion site, while the lower dose has begun to resolve by day 21.
At the higher dose, more of the compound is present, and due
to the poor solubility and slow delivery rate from the site, the
residence time of the material increases with dose.
It is known that shapes and sizes of a given material can
affect the capacity of macrophages to attach to and engulf a
foreign body (36). While crystal shapes and surface chemistries
are inherent properties particular to a chemical composition,
we have sought to size match the two ATAPs in our study so
that their size distributions achieve two main criteria: (1)
relevance to the product injected in each case (e.g. micron-
sized crystals, not nano-crystals), and (2) particle sizes exceed
that which macrophages can engulf. Prior experience with
aripiprazole indicates that precipitates that form in injection
sites are irritating, regardless of particle size control(31). We
therefore conclude that the impact of mass injected and the
chemical nature of the compound have a leading impact on
the resulting FBR.
In comparison with injection sites containing APZ, the
FBR to OLZ resolves at a faster rate. The kinetics and cyto-
kines present at the site differ in ways that are not solely due to
dose for mass adjustment, i.e. 300 mg OLZ, which is equiva-
lent to 143 mg olanzapine-free base (correcting for molecular
weight differences between the salt and the free base drug). If
the tissue response were purely mass based, the FBR following
SC administration of OLZ should roughly mimic that of APZ
at 100 mg. Clearly this is not the case, as the response to
100 mg of APZ is aggressive in comparison to the 300 mg
OLZ dose. Instead, other factors, such as solubility, lipophi-
licity, and resultant depot morphology following injection of
the individual compounds may also contribute to the tissue
response. The pharmacology of the active pharmaceutical
ingredient (API) likely also influences the response. It has been
observed that the chemical nature of the active drug compo-
nent can be the cause of chronic inflammation although the
mechanism is unclear (28, 33, 37). In these studies, it is evident
that different APIs indeed lead to distinct FBR, but this aspect
requires further investigation.
While there is a significant and potent FBR occurring at the
site of injection involving key cytokines, a concomitant system-
ic immune response is not detectable. There are no detectable
changes in the circulating immune cell population during the
reaction and no elevation of circulating cytokines is seen (data
not shown), further supporting the finding that the FBR is
localized to the injection site and surrounding tissue. This is
important to note, because unlike FBRs to inert inorganic
materials, drug particles dissolve over time and the drug is
absorbed into the body to elicit pharmacological effect remote
from the injection site.
In summary, LAIs of ATAPs induce a significant but
localized FBR at the site of injection and surrounding tissue.
This response is characterized by an early acute response
followed by a chronic inflammation phase. A surprising find-
ing is that the response to the two ATAPs could be differen-
tiated by both histopathology and by monitoring cytokine
release at the site of injection, indicating that not all drugs in
the same class are alike in this regard. Very little is known
about the interplay between the physico-chemical properties
of crystalline ATAPs and tissue dynamics at the site of injec-
tion. Future studies aimed at determining the mechanism of
the response and the chemical/cellular interactions control-
ling the response may provide new insight in controlling the
FBR and in designing the next generation of LAIs.
This work also establishes an experimental paradigm in
determining events, magnitude, and timing at the site of
injection from an immunological perspective. Currently, the
description of these reactions in the literature is limited.
Differences in the foreign body responses have been studied
in other areas such as implants. This work is the first study to
address and define the localized tissue reaction elicited by
poorly soluble crystalline LAIs of atypical antipsychotics de-
signed to reside in the tissue bed and release drug into the
body for an extended period of time.
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